久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Medivir Initiates Study of Birinapant in Combination with KEYTRUDA americanpharmaceuticalreview
    August 21, 2017
    Medivir announced the first patient has been enrolled in the company's phase I/II study of birinapant?in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab), which is marketed by MSD. The objectives of the study are to evaluate the safety, tol

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service